Azacitidine 是胞苷的核苷类似物,通过捕获DNA甲基,特异性抑制DNA methylation(DNA甲基化)。
5-Azacytidine (5-AZA), a cytidine analog,has been approved for the treatment of patients with acute myeloid leukemia(AML) and myelodyplastic syndrome (MDS). 5-Azacytidine is a potent growth inhibitor and a cytotoxic agent. DNA methyltransferase inhibitor. 5-Azacytidine acts as a demethylating agent by inhibiting DNA methyltransferase (Dnmt), forming covalent adducts with cellular DNMT1 depleting enzyme activity. Improves the efficiency of reprogramming of stem cells; induces differentiation of mesenchymal stem cells into cardiomyocytes.
30% Propylene glycol, 5% Tween 80, 65% D5W(5%葡萄糖水溶液)
Cell culture[1]
The cells were cultured in DMEM with theF-12 Ham’s nutrient supplemented with 10% of foetal bovine serum (FBS) and 1%P/S/A solution. During the experiment, the cells were cultured under asepticand constant conditions in an incubator (37°C, 5% CO2 and 95%humidity). The media were changed every 2 days and the cells were passagedusing trypsin solution according to manufacturers’ instructions after reaching80% confluence.
Pre-treatmentof ASCs with 5-AZA
Prior experiment ASCs were seeded onto24-well plates at the density of 20 x 103 per well. After cell attachmentculture medium was replaced with medium containing 5-AZA (1μM).After total pre-treatment (48 h) with 5-AZA, cells were maintained in standardculture medium again. Cells cultured in standard medium (DMEM, 10% of FBS, 1% P/S/A)without addition of 5-AZA served as a control group. Non-treated cells servedas a control for comparison with the test culture. All experiments wereperformed after seventh day of experiment.
Cellviability, population doubling time and colony forming unit-fibroblasts (CFU-fs)assay
Cell proliferation rate was evaluated using10% resazurin-based dye-TOX-8 following manufacturer’s protocols. To performthe test, culturemedia were removed and replaced with culture medium containing 10% of the dye.The cells were then incubated with the dye in the CO2 incubator,37°C for 2 hrs. Supernatants were collected and transferred to 96-well plate toperform the spectrophotometric assay. The absorbance of the supernatants wasmeasured at a wavelength of 600 nm for resazurin, and 690 nm referencewavelength. Each measurement included a blank sample, containing medium withoutcells. The number of cells was estimated on the basis of standard curve,generated during the experiment. To prepare the curve, cells were seeded at thedensity of 20x 103, 40 x 103, 80 x103 per welland dye absorbance was measured in relation to certain cells number. Lineartrendline equation allowed estimating cells number throughout the experiment.
To evaluate the ability of cells to formcolonies, ASCs were seeded in six-well plates at a density of 100 cells perwell and inoculated into a culture medium. The medium was changed every 2 daysand cultures were maintained for 7 days. After fixation in 4% ice-coldparaformaldehyde, cells were stained with pararosaniline solution and coloniesof more than 50 cells were counted and documented by a Power Shot Camera. Theefficiency of colony forming was calculated using the formula presented below.
Animals[2]
The C57BL/6 J mice (male, 6–8 weeks old,weighing 20–25 g) were fed with diet and water ad libitum under specificpathogen-free conditions and 12 h dark/light cycle.
APAP-inducedtoxic hepatitis
Toxic hepatitis was induced byintraperitoneal injection of APAP (350 mg/kg, dissolved in warm phosphatebuffered saline) in mice, vehicle or various doses of 5-AZA (1.25 mg/kg,2.5mg/kg, 5mg/kg, 10mg/kg, dissolved in normal saline, i.p.) was administered0.5 h prior to APAP exposure (n =8 per group). The animals were sacrificed by decapitationat 8 h after APAP exposure, blood and liver samples were harvested for furtherexperiments.
Survivalanalysis
To determine the effect of 5-AZA on themortality of APAP-exposed mice, lethal toxic hepatitis was induced byintraperitoneal injection of APAP (450 mg/kg), vehicle or 5-AZA (5 mg/kg) wasadministered 0.5 h prior to APAP exposure (n= 20 per group). The survival rateof these animals was assessed every 6 h for at least 7 days.
Histologicalanalysis
Formalin-fixed specimens were embedded inparaffin. Sections (4μm) were prepared and stained with hematoxylin & eosinroutinely for morphological evaluation under light microscope.
Determinationof aminotransferases
The ALT and AST activities in plasma wereassessed using the detection kits according to the manufacturer's instructions.
动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数 | |
例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。
[1] Kornicka K, Marycz K, Maredziak M, Tomaszewski KA, Nicpon J. The effects of the DNA methyltranfserases inhibitor 5-Azacitidine on ageing, oxidative stress and DNA methylation of adipose derived stem cells. J Cell Mol Med. 2017;21(2):387-401.
[2] Yang C, Yi J, Gong X, et al. Anti-oxidative and anti-inflammatory benefits of the ribonucleoside analogue 5-azacitidine in mice with acetaminophen-induced toxic hepatitis. Int Immunopharmacol. 2017;48:91-95.
[3] Broday, L., et al.: Mol. Cell Biol., 19, 3198 (1999)
[4] Qian, X., et al.: Am. J. Pathol., 153, 1475 (1999)
分子式 C8H12N4O5 |
分子量 244.2 |
CAS号 320-67-2 |
储存方式 ﹣20 ℃冷藏长期储存。冰袋运输 |
溶剂(常温) |
DMSO 49 mg/mL |
Water 50 mg/mL |
Ethanol 30 mg/mL |
体内溶解度
24 mg/mL
NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
NCT00901537 | Non-small Cell Lung Cancer|Squamous Cell Carcinoma of the Head and Neck | Drug: Azacitidine and Cisplatin | Loma Linda University | Phase 1 | 2009-02-01 | 2014-06-02 |
NCT01488565 | Myelodysplastic Syndromes (MDS)|Acute Myeloid Leukaemia (AML) | Drug: Azacitidine and eltrombopag | Peter MacCallum Cancer Centre, Australia|GlaxoSmithKline|Celgene Corporation | Phase 2 | 2010-12-01 | 2016-02-12 |
NCT02940483 | Brain Tumor Recurrent | Drug: 5-Azacytidine | The University of Texas Health Science Center, Houston | Early Phase 1 | 2016-12-01 | 2016-12-09 |
NCT01305460 | Myelodysplastic Syndrome | Drug: Azacitidine | Groupe Francophone des Myelodysplasies | Phase 1|Phase 2 | 2011-07-01 | 2015-10-28 |
NCT02038816 | Myelodysplastic Syndromes | Drug: Deferasirox + Azacitidine|Drug: Azacitidine | Sunnybrook Health Sciences Centre|Novartis | Phase 2 | 2014-03-01 | 2014-01-15 |
NCT02985190 | MDS|Systemic Autoimmune Diseases | Drug: Azacitidine | Groupe Francophone des Myelodysplasies|Celgene | Phase 2 | 2016-12-01 | 2016-12-02 |
NCT01305135 | High Grade Myelodysplastic Syndrome Lesions | Drug: azacitidine and idarubicin | Groupe Francophone des Myelodysplasies | Phase 1|Phase 2 | 2010-12-01 | 2015-10-28 |
NCT01379274 | MDS | Drug: Lenalidomide and azacitidine combination | Rush University Medical Center|Celgene Corporation | Phase 2 | 2011-01-01 | 2013-11-26 |
NCT01537744 | Solid Tumors|Virally Mediated Cancers and Liposarcoma | Drug: oral 5-azacitidine in combination with romidepsin | Sidney Kimmel Comprehensive Cancer Center|Celgene Corporation | Phase 1 | 2012-02-01 | 2017-03-21 |
NCT02323139 | MDS | Drug: Azacitidine and LDE255 | Groupe Francophone des Myelodysplasies|Novartis | Phase 1 | 2015-02-01 | 2016-05-30 |
NCT01599325 | Myelodysplastic Syndrome (MDS) | Drug: Azacitidine | Celgene | Phase 2 | 2012-07-01 | 2017-01-30 |
NCT01462578 | Acute Myelocytic Leukemia|Myelodysplastic Syndrome | Drug: Azacitidine | Technische Universit盲t Dresden | Phase 2 | 2011-09-01 | 2016-02-09 |
NCT01324960 | Myelodysplastic Syndromes | Drug: Ceplene庐, IL-2, Azacitidine|Drug: Azacitidine | Groupe Francophone des Myelodysplasies|EpiCept Corporation | Phase 1|Phase 2 | 2011-03-01 | 2014-03-19 |
NCT00795548 | Myelodysplastic Syndrome|Acute Myeloid Leukemia | Drug: 5-Azacitidine | Heinrich-Heine University, Duesseldorf | Phase 2 | 2008-11-01 | 2012-01-20 |
NCT00413478 | Chronic Lymphocytic Leukemia|Leukemia | Drug: 5-Azacytidine | M.D. Anderson Cancer Center|Celgene Corporation | Phase 2 | 2006-09-01 | 2015-06-26 |
NCT00387647 | Leukemia | Drug: Azacitidine | H. Lee Moffitt Cancer Center and Research Institute|Celgene Corporation | Phase 2 | 2006-08-01 | 2014-08-19 |
NCT02196857 | Leukemia | Drug: Azacytidine|Drug: Sorafenib | M.D. Anderson Cancer Center|Bayer | Phase 2 | 2015-02-01 | 2017-03-09 |
NCT01038635 | Leukemia | Drug: 5-Azacytidine|Drug: Lenalidomide | M.D. Anderson Cancer Center|Celgene | Phase 1|Phase 2 | 2009-12-01 | 2016-12-19 |
NCT00350818 | Myelodysplastic Syndrome|Leukemia | Drug: Azacitidine | M.D. Anderson Cancer Center|Celgene Corporation | Phase 1 | 2005-10-01 | 2012-07-27 |
NCT00721214 | Myelodysplastic Syndrome | Drug: 5-azacytidine | Virginia Commonwealth University|Celgene Corporation | Phase 2 | 2008-07-01 | 2016-02-03 |
NCT01913951 | Myelodysplastic Syndromes | Drug: vosaroxin|Drug: Azacitidine | Washington University School of Medicine | Phase 1 | 2013-11-22 | 2017-02-18 |
NCT00728520 | Acute Myeloid Leukemia|Elderly | Drug: Azacitidine | Kansas City Veteran Affairs Medical Center | Phase 2 | 2008-07-01 | 2008-08-05 |
NCT01652781 | Myelodysplastic Syndrome | Drug: Azacitidine | Seoul St. Mary's Hospital|Celgene Corporation | Phase 2 | 2012-03-01 | 2015-11-18 |
NCT02399917 | Leukemia | Drug: 5-azacytidine|Drug: Lirilumab|Behavioral: Phone Call | M.D. Anderson Cancer Center|Bristol-Myers Squibb | Phase 2 | 2015-04-01 | 2017-03-07 |
注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。
相关化合物库
使用AMQUAR产品发表文献后请联系我们